98%
921
2 minutes
20
Background: Early identification of children at risk of asthma attacks is important for optimizing treatment strategies. We aimed to integrate salivary microbiome and serum inflammatory mediator profiles with asthma attacks history to develop a comprehensive predictive model for future attacks.
Methods: This study contained a discovery (SysPharmPediA) and a replication phase (U-BIOPRED). School-aged children with asthma were classified into at risk and no-risk groups, based on the presence or absence of one or more severe attacks during one-year follow-up. Prediction models were developed using random forest on the training set (70%) with data on past asthma attacks, microbiome composition, serum inflammatory mediator levels, and their combinations and then tested on the rest of the population (30%). Outcomes were replicated in a subset of children with severe asthma from U-BIOPRED.
Results: Complete data were available for 154 children (SysPharmPediA = 121, U-BIOPRED = 33). In discovery, the model based on past attacks resulted in an area under the receiving characteristic curve (AUROCC) ~ 0.7. Models including six salivary bacteria or six inflammatory mediators achieved similar results. The combined model incorporating seven features, past asthma attacks, Capnocytophaga, Corynebacterium, and Cardiobacterium, TIMP-4, VEGF, and MIP-3β achieved the highest accuracy with AUROCC ~0.87. The combined model in the U-BIOPRED limited to available inflammatory mediators (VEGF), and incorporating past asthma attacks, Capnocytophaga, Corynebacterium, and Cardiobacterium, resulted in an AUROCC of 0.84.
Conclusion: Serum inflammatory mediators and salivary microbiome complement asthma attacks history for predicting future attacks. These results highlight the imperative for continued investigation into oral microbiota and its interaction with the immune system.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/all.70004 | DOI Listing |
Front Pediatr
August 2025
Paediatric Emergency Department, Ezkerraldea-Enkarterri-Cruces Integrated Health Organization, Cruces University Hospital, Basque Health Service-Osakidetza, Barakaldo, Spain.
Introduction: This study aims to evaluate the effectiveness and feasibility of the implementation of an Asthma Integrated Care Pathway (AICP) to improve care and reduce variability according to recommended clinical practice guidelines, for children presenting with acute asthma episodes in paediatric primary care, and hospital services including emergency departments.
Methods And Analysis: A cluster quasi-experimental implementation trial with a matched control group will be launched in a regional healthcare service. All the paediatric healthcare professionals providing care in two health districts (HDs) will receive interventions over two 12-month periods during which components of the implementation strategy to favour adoption of the AICP will be deployed cumulatively.
Eur Ann Allergy Clin Immunol
September 2025
Allergology Unit, San Carlo Clinic, Paderno Dugnano, Milan, Italy.
Chronic spontaneous urticaria (CSU) is a common disorder characterized by the recurrence of wheals and/or angioedema for more than 6 weeks. About 35% of patients experience wheals and angioedema (AE-CSU) and around 6% of patients only present angioedema, also known as chronic histaminergic angioedema (CHA). As few data comparing CHA and AE-CSU are published, we analyzed the differences between demographic and clinical characteristics of these populations.
View Article and Find Full Text PDFJ Allergy Clin Immunol Pract
August 2025
Institute of Allergology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universitätsmedizin Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany. Electronic a
Background: Poor compliance with hereditary angioedema guidelines for on-demand treatment is common due to challenges with parenteral administration. Sebetralstat, an oral plasma kallikrein inhibitor, demonstrated faster times to beginning of symptom relief, reduction in attack severity, and complete resolution than placebo in the phase 3 KONFIDENT trial (NCT05259917).
Objective: This analysis evaluated long-term safety and effectiveness of sebetralstat in KONFIDENT-S (NCT05505916), an ongoing, 2-year, open-label extension study.
Leg Med (Tokyo)
August 2025
Department of Legal Medicine, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3 Asahi-machi, Abeno, Osaka 545-8585, Japan.
We report a case of death due to thallium (Tl) poisoning and discuss the findings with reference to the literature on Tl poisoning. A woman in her 20 s with a history of asthma developed symptoms such as coughing, vomiting, and fatigue, and visited a primary-care physician. She was rushed to another hospital on suspicion of an asthma attack, but her condition suddenly worsened and she died 3 days later.
View Article and Find Full Text PDFAdv Ther
August 2025
King Fahad Medical City, Riyadh, Saudi Arabia.
Introduction: Before the availability of biologic therapies, the main treatment for patients with severe asthma in Asia, Latin America, and the Middle East was oral corticosteroids (OCS), despite long-term use causing serious adverse effects. This post hoc analysis of the NUCALA Effectiveness Study (NEST) evaluated the effectiveness of mepolizumab, an anti-interleukin-5 monoclonal antibody, in patients with severe asthma and OCS dependence from regions with limited representation in real-world studies.
Methods: NEST was a multicountry, observational cohort study in adults with severe asthma from Colombia, Chile, India, Türkiye, Saudi Arabia, United Arab Emirates, Kuwait, Oman, and Qatar.